-
FDA accepts Endo's resubmission for Opana ER
CHADDS FORD, Pa. — The Food and Drug Administration has accepted a resubmission by Endo Pharmaceuticals of a regulatory application for an opioid pain drug designed to thwart abuse, Endo said.
The agency had declined to approve Endo’s Opana ER (oxymorphone hydrochloride) in January for reasons that the company did not specify, though the agency did not request additional clinical studies in its statement, known as a complete response letter.
-
Chris Noth tapped as ambassador for Ask.Screen.Know.
PRINCETON, N.J. — Novo Nordisk has teamed up with actor Chris Noth to underscore the importance of early diabetes screening and detection.
Noth will serve as an ambassador for the national education program Ask.Screen.Know., Novo Nordisk said. As an ambassador, Noth will encourage Americans ages 45 years or older to get tested for diabetes and talk to a healthcare professional about the risk factors through a public service announcement and online at AskScreenKnow.com.